BCR and Miyoshi myopathy: In addition, small qualitative and/or quantitative variations in specificity/potency observed for the promiscuous BCR TK inhibitor profiles of WA and IBR may not be sufficient to explain the large difference in the therapeutic efficacy of WA as compared to IBR against GC-resistant MM cell lines.